Akoya Biosciences, Inc.

NasdaqGS:AKYA Rapporto sulle azioni

Cap. di mercato: US$104.6m

Akoya Biosciences Gestione

Gestione criteri di controllo 3/4

Akoya Biosciences Il CEO è Brian McKelligon, nominato in Jul2017, e ha un mandato di 7.33 anni. la retribuzione annua totale è $ 2.92M, composta da 18.6% di stipendio e 81.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.075% delle azioni della società, per un valore di $ 78.56K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.4 anni e 4.3 anni.

Informazioni chiave

Brian McKelligon

Amministratore delegato

US$2.9m

Compenso totale

Percentuale dello stipendio del CEO18.6%
Mandato del CEO7.3yrs
Proprietà del CEO0.08%
Durata media del management2.4yrs
Durata media del Consiglio di amministrazione4.3yrs

Aggiornamenti recenti sulla gestione

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

May 29
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

Recent updates

Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Nov 19
Revenue Downgrade: Here's What Analysts Forecast For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt?

Nov 12
Is Akoya Biosciences (NASDAQ:AKYA) Using Too Much Debt?

Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company

Oct 08
Akoya Biosciences, Inc. (NASDAQ:AKYA) Stock Rockets 36% But Many Are Still Ignoring The Company

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Aug 09
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported, And Analysts Assigned A US$5.42 Price Target

Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost

Jun 27
Market Might Still Lack Some Conviction On Akoya Biosciences, Inc. (NASDAQ:AKYA) Even After 31% Share Price Boost

Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

Jun 24
Is Akoya Biosciences (NASDAQ:AKYA) A Risky Investment?

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

May 29
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Akoya Biosciences, Inc.'s (NASDAQ:AKYA) CEO For Now

Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)

May 10
Investors Continue Waiting On Sidelines For Akoya Biosciences, Inc. (NASDAQ:AKYA)

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Feb 28
Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Nov 25
Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Akoya Biosciences Seeks Growth Despite Higher Operating Losses

May 30

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11
Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Brian McKelligon rispetto agli utili di Akoya Biosciences?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$58m

Jun 30 2024n/an/a

-US$60m

Mar 31 2024n/an/a

-US$68m

Dec 31 2023US$3mUS$543k

-US$63m

Sep 30 2023n/an/a

-US$71m

Jun 30 2023n/an/a

-US$76m

Mar 31 2023n/an/a

-US$73m

Dec 31 2022US$3mUS$518k

-US$71m

Sep 30 2022n/an/a

-US$69m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$51m

Dec 31 2021US$2mUS$393k

-US$44m

Sep 30 2021n/an/a

-US$34m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$28m

Dec 31 2020US$516kUS$350k

-US$22m

Dec 31 2019US$484kUS$333k

-US$18m

Compensazione vs Mercato: La retribuzione totale di Brian ($USD 2.92M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 649.07K ).

Compensazione vs guadagni: La retribuzione di Brian è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Brian McKelligon (55 yo)

7.3yrs

Mandato

US$2,919,599

Compensazione

Mr. Brian McKelligon has been Chief Executive Officer and Director at Akoya Biosciences, Inc. since July 2017 and also serves as its President. Prior to joining Akoya, he led corporate and business develop...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Brian McKelligon
President7.3yrsUS$2.92m0.075%
$ 78.6k
John Ek
CFO, Principal Financial Officer & Principal Accounting Officer1.7yrsUS$2.37m0.092%
$ 96.5k
Anthony Catalano
Senior Vice President of Operationsno dataNessun datoNessun dato
Priyam Shah
Senior Director of Business Development & Investor Relations Strategyno dataNessun datoNessun dato
Jennifer Kamocsay
Chief Legal Officer1.8yrsNessun dato0.012%
$ 12.9k
Niro Ramachandran
Chief Business Officer4.3yrsUS$365.22k0.29%
$ 305.5k
Pascal Bamford
Senior Vice President of Research & Development and Laboratory Operations3.1yrsNessun dato0.17%
$ 174.6k
Rob Hart
Secretaryno dataNessun datoNessun dato

2.4yrs

Durata media

51yo

Età media

Gestione esperta: Il team dirigenziale di AKYA è considerato esperto (durata media dell'incarico 2.4 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Brian McKelligon
President7.3yrsUS$2.92m0.075%
$ 78.6k
Robert Shepler
Independent Director9yrsUS$251.66k0.75%
$ 779.8k
Myla Lai-Goldman
Independent Director3.2yrsUS$237.50k0.040%
$ 42.2k
Thomas Schnettler
Independent Director5.2yrsUS$220.00k0%
$ 0
Thomas Raffin
Director9yrsUS$210.00k0.47%
$ 495.0k
Matthew Winkler
Independent Director7.3yrsUS$232.50k1.99%
$ 2.1m
James Allison
Member of Scientific Advisory Boardless than a yearNessun datoNessun dato
Scott Mendel
Independent Chairman3.4yrsUS$250.00k0.058%
$ 60.1k
Padmanee Sharma
Member of Scientific Advisory Boardless than a yearNessun datoNessun dato
Garry Nolan
Chair of the Scientific Advisory Boardless than a yearUS$220.00k1.24%
$ 1.3m

4.3yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AKYA sono considerati esperti (durata media dell'incarico 4.3 anni).